Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bumrungrad Hospital PCLBUGDF 100 3-Year EPS without NRI Growth Rate is 15.10% as of Mar. 2026, which is 32% above its 10-year median of 11.40. GuruFocus rates BUGDF with a GF Score™ of 100/100 and a GF Value™ of $5.72. The stock has 1 warning sign investors should review. Among 508 Healthcare Providers & Services companies, Bumrungrad Hospital PCL ranks better than 55.71% on this metric.
During the past 12 months, Bumrungrad Hospital PCL's average EPS without NRI Growth Rate was 0.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 15.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 53.40% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Bumrungrad Hospital PCL was 83.40% per year. The lowest was -32.80% per year. And the median was 11.40% per year.
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bumrungrad Hospital PCL 3-Year EPS without NRI Growth Rate Related Terms
BUGDF vs HCA, THC, DVA: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Care Facilities subindustry, Bumrungrad Hospital PCL's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bumrungrad Hospital PCL 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Bumrungrad Hospital PCL's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bumrungrad Hospital PCL's 3-Year EPS without NRI Growth Rate falls into.
Bumrungrad Hospital PCL 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 15.10% mean?
Bumrungrad Hospital PCL (BUGDF) has a 3-Year EPS without NRI Growth Rate of 15.10% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bumrungrad Hospital PCL and its competitors. This is 32% above median its historical median of 11.40. According to the industry distribution chart, Bumrungrad Hospital PCL ranks #225 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 44.3%.
Is Bumrungrad Hospital PCL's 3-Year EPS without NRI Growth Rate too high?
Bumrungrad Hospital PCL's current 3-Year EPS without NRI Growth Rate of 15.10% is 32% above median its 10-year median of 11.40. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.30. Bumrungrad Hospital PCL's value of 15.10% is 33.6% above this industry median. Based on the distribution chart, Bumrungrad Hospital PCL ranks #225 out of 508 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Bumrungrad Hospital PCL has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Bumrungrad Hospital PCL's 3-Year EPS without NRI Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Bumrungrad Hospital PCL ranks #225 out of 508 companies for 3-Year EPS without NRI Growth Rate. This puts Bumrungrad Hospital PCL in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.30. Bumrungrad Hospital PCL's value of 15.10% is 33.6% above this benchmark. While the company's 10-year median is 11.40 vs. the industry median of 11.30, Bumrungrad Hospital PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.30, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bumrungrad Hospital PCL's current 3-Year EPS without NRI Growth Rate of 15.10% is 33.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bumrungrad Hospital PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bumrungrad Hospital PCL's current 3-Year EPS without NRI Growth Rate is 15.10%, which is 32% above median its own 10-year median of 11.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bumrungrad Hospital PCL stock overvalued right now?
Bumrungrad Hospital PCL (BUGDF) has a current 3-Year EPS without NRI Growth Rate of 15.10%. The stock's GF Value™ is $5.72, compared to a current price of $4.75 — trading 17% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 15.10%, which is 32% above median its 10-year median of 11.40 and 33.6% above the Healthcare Providers & Services industry median of 11.30. Bumrungrad Hospital PCL's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bumrungrad Hospital PCL (BUGDF), the current 3-Year EPS without NRI Growth Rate is 15.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bumrungrad Hospital PCL (BUGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Bumrungrad Hospital PCL stock appears to be undervalued.
The current stock price of $4.75 is trading 17% below its estimated GF Value™ of $5.72.
Key valuation signals for BUGDF:
3-Year EPS without NRI Growth Rate: 15.10% (32% above median its 10-year median of 11.40)
GF Value™: $5.72 vs. price of $4.75 (17% below fair value)
Industry Position: 33.6% above the Healthcare Providers & Services median (#225 of 508)
No single metric tells the full story. See the BUGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bumrungrad Hospital PCL operates a private hospital business in Bangkok. The company operates several healthcare-related entities, within and outside of Thailand which include Bumrungrad International Hospital, Bumrungrad International Clinic, Vitallife Scientific Wellness Center, VitalLife Skin Clinic, Bumrungrad International Dialysis Clinic, and others. It is a healthcare provider in Thailand providing complete healthcare services for both outpatients and inpatients. The company is the owner and operator of multiple healthcare-related entities. The company has only one main reportable operating segment, which is the hospital and health care center business, and the geographical area of its operations is Thailand.
100GF Score
Get the complete analysis for BUGDF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUGDF has been successfully added to your 
